Star Health Q1 FY27 profit rises 26% to ₹5.5bn

Q1 result: profit rises year-on-year

Star Health and Allied Insurance Company Limited reported its financial results for the quarter ended June 30, 2026 (Q1 FY27). The standalone health insurer posted standalone net profit of ₹55.0 billion, up from ₹43.8 billion in the corresponding period last year. The company indicated this translates into approximately 25.57% year-on-year growth. The update positions the quarter as a continuation of the profitability momentum the company reported in the preceding financial year. The company also linked the improvement to underwriting metrics and steady retail premium trends. The results were communicated as part of the company’s Q1 FY27 disclosure cycle.

What supported the quarter’s performance

In its commentary, Star Health attributed the rise in profitability to stronger underwriting outcomes and operational momentum. It also pointed to persistent retail premiums as a supporting factor. The company described the quarter as building on a turnaround achieved in the previous year. While detailed line-by-line quarterly operating metrics were not provided in the shared text, the company’s narrative emphasised underwriting discipline. The context is important for a standalone health insurer, where claim costs and expense efficiency typically drive the combined ratio and, ultimately, profits.

Underwriting turnaround remains a key reference point

A major anchor for the company’s narrative is the improvement in underwriting results in FY26. Star Health reported an underwriting profit of ₹20.6 billion in FY26, reversing an underwriting loss of ₹16.5 billion in FY25. That shift is highlighted as “structural improvement” in underwriting. For investors, the underwriting swing helps explain why profit growth is being framed as more durable than a one-quarter effect. The company has positioned Q1 FY27 as an extension of that trajectory.

FY26 snapshot: premiums, profits, and combined ratio

For the full year FY26, Star Health reported Gross Written Premium (GWP) of ₹2,036.9 billion, representing 16% year-on-year growth. Profit After Tax (PAT) under IndAS for FY26 stood at ₹91.1 billion, up 16% from ₹78.7 billion in the previous year. The combined ratio improved to 98.8% in FY26 from 101.1% in FY25. A combined ratio below 100% is generally associated with underwriting profitability, and the company’s FY26 figure is consistent with the underwriting profit it reported for the year. These FY26 data points provide the backdrop against which Q1 FY27 profit growth is being read.

Management guidance: FY27 GWP target and product push

Star Health’s management set a GWP target of ₹2,400.0 billion for FY27. This is higher than the FY26 GWP base of ₹2,036.9 billion cited in the results commentary. The company also announced plans to launch affordable, customised products aimed at tier-2 and tier-3 towns. The stated intent is to deepen insurance penetration through product design and distribution focus. The updates indicate a growth push anchored in retail health, which is central to the company’s positioning as a standalone health insurer.

Stock snapshot and key listed-company metrics

On the market screen shared with the results context, Star Health’s stock was shown at ₹572.65, down ₹10.75 (1.84%), with the timestamp indicating BSE at 04:01 PM on June 24. The day’s high was ₹588.8 and the day’s low was ₹572.55. The 52-week high and low were listed as ₹597.3 and ₹413.15, respectively. Market capitalisation was shown as ₹33,658.14 crore, with enterprise value at ₹33,459.71 crore. The same snapshot listed a P/E of 60.43 and P/B of 4.44, with promoter holding at 57.98%.

Peer context: ICICI Lombard’s Q1FY27 pressure points

In the same broader discussion on retail health insurance, ICICI Lombard General Insurance Co. was cited as seeing its stock drop over 10% to ₹1,610 after Q1FY27 results. The text highlighted that ICICI Lombard’s retail health business had strong growth, with gross direct premium income from retail health under its Elevate product rising 69.5% year-on-year to ₹71.8 billion in Q1FY27. However, even after excluding one-off impacts from two large fire claims of ₹6.3 billion and an additional ₹16.5 billion provision linked to a Supreme Court ruling on motor third-party claims dated June 11, the combined ratio worsened to 103.4% from 102.9% a year ago. Net profit declined 23% year-on-year to ₹57.5 billion. This comparison underscores how combined ratio movement can outweigh premium growth in near-term profitability.

Governance and upcoming investor interaction

Ahead of the Q1 FY27 results, the company noted that the trading window for designated persons was closed from July 1, 2026, until 48 hours after the results announcement. Separately, Star Health announced it will host its Q1 FY27 earnings call on July 30, 2026 at 08:30 AM IST to discuss performance for the quarter ended June 30, 2026. The company said the call is being held pursuant to Regulation 30(6) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Management participants listed for the call included the Managing Director and CEO, Executive Director and COO, Executive Director and CMO, CFO, CIO, and the head of investor relations. Access was made available via pre-registration and operator-assisted dial-in.

Key numbers at a glance

Market impact: what the data implies, without forecasting

The immediate market takeaway from Star Health’s Q1 FY27 update is that profit improved meaningfully year-on-year, supported by the company’s emphasis on underwriting strength. FY26 combined ratio improvement to 98.8% from 101.1% provides a reference for why profitability has stabilised after a weaker FY25 underwriting outcome. The FY27 GWP target of ₹2,400.0 billion is also a concrete data point for investors tracking execution versus stated ambition. At the same time, the stock snapshot shows the share price moving lower on the day referenced, indicating that broader market factors and expectations can still dominate near-term trading. The peer discussion around ICICI Lombard highlights how combined ratio deterioration can pressure profits even amid strong premium growth.

Conclusion

Star Health’s Q1 FY27 standalone net profit rose to ₹55.0 billion from ₹43.8 billion a year earlier, a year-on-year increase of about 25.57%. The company is framing the quarter as a continuation of its FY26 underwriting and combined ratio improvement, while also setting a FY27 GWP target of ₹2,400.0 billion. The next formal milestone for investors is the scheduled Q1 FY27 earnings call on July 30, 2026 at 08:30 AM IST, where management is expected to discuss the quarter ended June 30, 2026 in more detail.